U.S. Household Products Stock News

Ardagh Metal Packaging (AMBP) has given investors plenty to think about after reporting 2025 results that exceeded its own guidance, outlining 2026 adjusted EBITDA growth expectations, completing a US$1.3b green bond refinancing, and affirming a quarterly dividend. See our latest analysis for Ardagh Metal Packaging. The recent earnings beat, 2026 EBITDA guidance and US$1.3b green bond refinancing sit against a share price of US$4.85, with a 30 day share price return of 10.48% and a 1 year...

Event overview and immediate context Generate Biomedicines (GENB) recently drew investor attention after a single day move of about 3.8% and a year to date return of roughly a 23.9% decline, prompting closer scrutiny of its drug discovery model and early stage pipeline. See our latest analysis for Generate Biomedicines. For now, the 1 day share price return of about 3.8% and year to date share price return of roughly a 23.9% decline suggest sentiment has cooled, even as interest in its...

LCI Industries (NYSE:LCII) has signaled ongoing interest in acquisitions, highlighting a renewed focus on M&A within its core markets. The company referenced a history of completed deals and expressed intentions to build on recent M&A momentum. This more active approach to acquisitions could influence LCI Industries' growth path, competitive position and capital deployment priorities. For investors watching NYSE:LCII, the renewed emphasis on acquisitions comes as the shares trade at...

Empire State Realty OP (ESBA) just wrapped up FY 2025 with Q4 total revenue of US$199.7 million and basic EPS of US$0.13, while trailing twelve month revenue sits at US$768.3 million and EPS at US$0.27. Over the past few quarters, revenue has moved from US$197.6 million in Q4 2024 to US$199.7 million in Q4 2025, with quarterly EPS shifting from US$0.07 to US$0.13. This sets up a picture where investors will be weighing these earnings against a 9.5% net margin and the impact of a one off gain...

Investors may be wondering whether Kroger, at around its recent US$69.05 close, is still a reasonable entry point or if most of the easy value is already on the table. The stock has returned 1.2% over the last 7 days, 9.9% over the past month, 9.7% year to date, 12.0% over 1 year, 58.7% over 3 years and 121.0% over 5 years. These returns may have shifted how the market views its risk and return trade off. Recent coverage has focused on Kroger's ongoing position as a major US grocery chain...

UroGen Pharma FY 2025 results set the stage for growth versus losses debate UroGen Pharma (URGN) closed out FY 2025 with Q4 revenue of US$37.8 million and a basic EPS loss of US$0.54, alongside a trailing twelve month loss of US$3.19 per share on US$109.8 million of revenue. The company has seen quarterly revenue move from US$24.6 million in Q4 2024 to US$37.8 million in Q4 2025. Over the same period, basic EPS ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.54 in the latest...

Interactive Brokers Group (NasdaqGS:IBKR) reports strong growth in client activity and trading volumes. The broker launches stablecoin funding for U.S. clients, allowing deposits in certain digital dollar tokens. The company highlights continued progress in brokerage technology and its inclusion in the S&P 500 Index. Interactive Brokers Group, trading at around $71.67, sits in a very different place than it did a few years ago, with a 1 year return of 43.0% and a 5 year return of 288.5%...

Immunome, Inc. recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, updating investors on its oncology-focused pipeline and regulatory plans. A key highlight is the company’s push toward a New Drug Application for Varegacestat in desmoid tumors, alongside multiple upcoming solid tumor IND submissions and an FDA-cleared radioligand therapy trial. We’ll now examine how Immunome’s renewed oncology focus and advancing Varegacestat program might influence the company’s...

If you are wondering whether Bunge Global’s current share price lines up with its underlying worth, this article walks through the key numbers that matter for valuation. The stock recently closed at US$120.61, after a 0.6% decline over 7 days, a 5.9% gain over 30 days, and returns of 30.2% year to date, 73.1% over 1 year, 34.3% over 3 years, and 75.8% over 5 years. Recent coverage has focused on Bunge Global’s role in global agribusiness and food supply chains and how that positioning may...

Cullen/Frost Bankers (CFR) has drawn fresh attention after recent trading, with the share price closing at $140.21 and posting mixed short term returns while still showing gains over the past 3 months and year. See our latest analysis for Cullen/Frost Bankers. The recent 1 day share price return of 1.44% sits against a 7 day share price return of negative 1.35%. At the same time, the 90 day share price return of 13.93% and 1 year total shareholder return of 7.14% point to momentum that has...

Apogee Therapeutics reported a full-year net loss of US$255.84 million for 2025, with basic and diluted loss per share of US$4.22 as it continued to report no product revenue while investing heavily in its antibody pipeline. Alongside deeper losses, the company underscored upcoming clinical milestones for zumilokibart and other programs and filed a US$287.29 million shelf registration tied to an employee stock ownership plan, highlighting both capital needs and efforts to align employee...

NVR recently reported its fourth-quarter 2025 results, with earnings and Homebuilding revenue coming in ahead of consensus estimates despite weaker housing demand and affordability pressures. An interesting wrinkle is that, even with this earnings beat, analyst estimates for NVR have generally moved lower, pointing to a more cautious outlook on future performance. Next, we will examine how beating expectations amid softer housing demand shapes NVR's investment narrative for investors...

uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term...

If you are wondering whether NBT Bancorp is reasonably priced or offering a margin of safety at its current US$42.78 share price, you are in the right place to get a clear, valuation focused view. The stock has slipped 2.0% over the last week and 3.7% over the last month, while still showing a 2.9% return year to date and longer term returns of 21.9% over 3 years and 22.7% over 5 years. These movements may signal shifting views on both its potential and its risks. Recent coverage of regional...

LXP Industrial Trust (LXP) has put fresh numbers in front of investors with its Q4 2025 investor presentation, spotlighting 97.1% portfolio occupancy and a new approximately 1 million square foot Phoenix development tied to strong industrial demand. See our latest analysis for LXP Industrial Trust. At a share price of $49.09, LXP Industrial Trust has seen a 15.53% 1 year total shareholder return, even though its year to date share price return is slightly negative and short term moves remain...

If you are wondering whether Alignment Healthcare is attractively priced at its current level, this article will walk through how the market might be valuing the stock today and what that could mean for you. The share price closed at US$19.65 recently, with returns of a 1.3% decline over the last week, a 12.8% decline over the last month, a 2.8% decline year to date, and a 26.6% gain over the past year, as well as a very large gain over three years. These moves have come alongside ongoing...

Limbach Holdings (LMB) is back in focus after reporting fourth quarter and full year 2025 results, with higher sales, net income and earnings per share compared with the prior year periods. See our latest analysis for Limbach Holdings. The latest earnings release comes after a strong run in the shares, with a 90 day share price return of 29.7% and a 1 year total shareholder return of 15.65%. The 3 year total shareholder return is around 7x, and recent weekly moves have cooled short term...

For investors wondering if Century Communities at around US$65.99 offers solid value, this article walks through what the numbers indicate about the stock today. The share price has seen mixed recent returns, with about a 5.7% decline over the last 7 days, a 4.8% gain over 30 days, around 12.0% year to date, and roughly a 1.0% decline over the past year. This combination can leave investors unsure how to interpret the risk and reward trade off. Recent coverage of homebuilders and housing...

Doximity, Inc. recently presented at the ViVE 2026 conference in Los Angeles, where co-founder and CEO Jeffrey A. Tangney outlined the company’s latest digital healthcare tools and platform capabilities for medical professionals. This appearance, alongside upbeat analyst commentary on Doximity’s role in telemedicine and clinician workflow, has sharpened investor focus on its position in digital healthcare. Next, we’ll explore how this heightened attention on Doximity’s telemedicine and...

If you are wondering whether TJX Companies is still good value at around US$159.94 per share, it helps to step back and look at what the recent share price and fundamentals are really telling you. The stock has returned 1.4% over the last 7 days, 6.8% over the past month, 3.7% year to date, 31.0% over 1 year and 112.9% and 164.0% over 3 and 5 years respectively, so many investors are asking whether the current price already reflects these outcomes. Recent coverage around TJX has focused on...

If you are trying to figure out whether Healthpeak Properties is reasonably priced or offering a margin of safety, this article walks through what the current share price might be implying. The stock last closed at US$17.63, with returns of 1.9% over the past week, 2.3% over the past month, 8.8% year to date, and a 7.9% decline over the last year. This may leave you wondering whether the recent moves reflect changing risk or opportunity. Recent news flow around Healthpeak Properties has...

Tsakos Energy Navigation (NYSE:TEN) declared a regular quarterly cash dividend for its Series F Cumulative Redeemable Perpetual Preferred Shares. The dividend applies to the current quarter and is payable to holders of record as of the announced record date. This decision highlights the company’s ongoing approach to returning capital to preferred shareholders. Tsakos Energy Navigation operates in the international tanker shipping sector, focusing on the transport of crude oil and refined...

Why short interest around Mondelez International (MDLZ) matters now Recent attention on Mondelez International (MDLZ) has centered on short interest activity in the stock, coming at a time when the company reports consistent revenue growth and stable demand for its global snack brands. For you as an investor, that combination of evolving short positions and steady business performance raises practical questions about sentiment, potential risks, and whether current pricing reflects the...

Xeris Biopharma Holdings (XERS) closed out FY 2025 with fourth quarter revenue of US$85.8 million, basic EPS of US$0.07, and net income of US$11.1 million. On a trailing twelve month basis, revenue was US$291.8 million and basic EPS was US$0.00, reflecting a small net profit of US$0.6 million. The company has seen revenue move from US$203.1 million and basic EPS of a US$0.37 loss on a trailing basis in Q4 2024 to US$291.8 million and essentially breakeven EPS by Q4 2025. That shift toward...